Research graph
References from Cost-effectiveness analysis of penpulimab plus anlotinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
10.3322/caac.21834
10.3322/caac.21834 · External reference
10.1016/j.jncc.2024.01.006
10.1016/j.jncc.2024.01.006 · External reference
10.20892/j.issn.2095-3941.2022.0449
10.20892/j.issn.2095-3941.2022.0449 · External reference
10.3389/fimmu.2024.1444091
10.3389/fimmu.2024.1444091 · External reference
10.1056/nejmoa1915745
10.1056/nejmoa1915745 · External reference
10.1016/j.jhep.2021.11.030
10.1016/j.jhep.2021.11.030 · External reference
10.1016/j.jhep.2025.03.033
10.1016/j.jhep.2025.03.033 · External reference
10.1016/s1470-2045(25)00190-1
10.1016/s1470-2045(25)00190-1 · External reference
10.1155/2013/725305
10.1155/2013/725305 · External reference
Unresolved reference
2020 · External reference
Unresolved reference
External reference
10.1007/s40273-013-0064-3
10.1007/s40273-013-0064-3 · External reference
Unresolved reference
External reference
10.1177/11795549241299393
10.1177/11795549241299393 · External reference
10.1177/17562848241310314
10.1177/17562848241310314 · External reference
10.1136/bmjopen-2023-079603
10.1136/bmjopen-2023-079603 · External reference
10.1007/s12325-022-02079-4
10.1007/s12325-022-02079-4 · External reference
10.1186/s12913-022-08661-4
10.1186/s12913-022-08661-4 · External reference
10.1186/s12955-020-01598-4
10.1186/s12955-020-01598-4 · External reference
10.3390/biomedicines12071624
10.3390/biomedicines12071624 · External reference
10.3390/jcm12237469
10.3390/jcm12237469 · External reference
10.1186/s12913-023-10409-7
10.1186/s12913-023-10409-7 · External reference
Chinese expert consensus on the use of standardized second-line drugs for primary hepatocellular carcinoma
2026 · External reference
10.5435/jaaos-d-23-00061
10.5435/jaaos-d-23-00061 · External reference
10.3389/fimmu.2025.1591517
10.3389/fimmu.2025.1591517 · External reference
10.1016/j.urolonc.2016.06.003
10.1016/j.urolonc.2016.06.003 · External reference
10.1007/s40273-024-01366-y
10.1007/s40273-024-01366-y · External reference
10.1080/07853890.2025.2482019
10.1080/07853890.2025.2482019 · External reference
10.1007/s44446-025-00042-2
10.1007/s44446-025-00042-2 · External reference
10.1371/journal.pone.0337606
10.1371/journal.pone.0337606 · External reference
10.3389/fphar.2025.1556304
10.3389/fphar.2025.1556304 · External reference
10.1136/bmjopen-2024-094804
10.1136/bmjopen-2024-094804 · External reference
10.1016/s1470-2045(21)00252-7
10.1016/s1470-2045(21)00252-7 · External reference
10.1016/s1470-2045(25)00543-1
10.1016/s1470-2045(25)00543-1 · External reference
